Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Neurology,Neurology,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11060-005-9020-1.pdf
Reference12 articles.
1. Soffietti R, Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin Pharmacother 5: 295–306, 2004
2. van den Bent MJ, Kros JM, Heimans JJ, et al Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group Neurology 51: 1140–1145, 1998
3. Cairncross JG, Aggressive oligodendroglioma: a chemosensitive tumor. Recent Res Cancer Res 135: 127–133, 1994
4. van den Bent MJ, Taphoorn MJ, Brandes AA, et al: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21: 2525–2528, 2003
5. van den Bent MJ, Chinot O, Boogerd W, et al: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14: 599–602, 2003
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Current and Future Frontiers of Molecularly Defined Oligodendrogliomas;Frontiers in Oncology;2022-07-25
2. First-line chemotherapeutic treatment for oligodendroglioma, WHO grade 3—PCV or temozolomide?;Neuro-Oncology Practice;2022-03-17
3. Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation;Neuro-Oncology Practice;2022-01-14
4. Oligodendroglioma: A Review of Management and Pathways;Frontiers in Molecular Neuroscience;2021-10-05
5. Treatment of anaplastic gliomas: evidences and controversies;Current Opinion in Oncology;2021-08-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3